Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

NLNK $16.96 1.0800 +6.80%
PVCT $0.52 0.0200 +4.00%
SNTA $0.44 0.0159 +3.78%
CTIC $0.54 0.0180 +3.42%
CLDX $4.32 0.1300 +3.10%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $7.03 -1.4200 -16.80%
GILD $92.12 -4.8800 -5.03%
RXDX $6.45 -0.3400 -5.01%
MNKD $1.39 -0.0483 -3.35%
PPHM $0.36 -0.0119 -3.21%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Will Medicare's Physician Payment Overhaul Drive More Docs To Hospitals?

(Modern Healthcare) Apr 27, 2016 - The CMS on Wednesday began to answer some of the many questions about how physicians will get paid under the Medicare Access and CHIP Reauthorization Act. But some stakeholders were immediately dissatisfied with what they saw, and the 963-page rule may have raised as many questions as it answered.
read article (free registration required) 

Sanofi Stalks Medivation With $9.3 Billion on Being Spurned

(Bloomberg) Apr 28, 2016 - Sanofi, the French drugmaker under siege for its lackluster pipeline of new medicines, made public an unsolicited offer to buy Medivation Inc. for about $9.3 billion in cash to gain experimental cancer therapies.
read article 

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma

(Advaxis) Apr 28, 2016 - Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
read corporate press release 

Rebates Offset Drug Prices -- Why Not Let Patients Benefit?

(Forbes) Apr 26, 2016 - The neediest patients with the highest costs don’t benefit much from price concessions. That’s due for a change.
read article 

Florida Cancer Specialists’ Physician Named FLASCO President for Second Term

(FCS) Apr 25, 2016 - Florida Cancer Specialists & Research Institute (FCS) is pleased to announce Michael Diaz, MD, who serves on the FCS Executive Board, has been named President of the Florida Society of Clinical Oncology (FLASCO) for a second consecutive term.
read press release 

Adimab Announces Antibody Discovery Collaboration with Takeda

(Yahoo! Finance) Apr 26, 2016 - Adimab LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Takeda Pharmaceutical Company Ltd.
read article 

Valeant Was 'Too Aggressive' in Pricing, CEO to Tell Senate

(Bloomberg) Apr 27, 2016 - Valeant Pharmaceuticals International Inc. was too aggressive in raising prices, outgoing Chief Executive Officer Mike Pearson will tell U.S. senators on Wednesday at a committee hearing to examine the cost of prescription drugs.
read article 

The Complex Math Behind Spiraling Prescription Drug Prices

(New York Times) Apr 27, 2016 - The soaring cost of prescription drugs has generated outrage among politicians and patients. Some cancer drugs carry price tags of more than $100,000 a year, and health plans are increasingly asking people to shoulder a greater share of the cost.
read article 

Drug Prices Keep Rising Despite Intense Criticism

(New York Times) Apr 26, 2016 - The burden of drug pricing often falls most heavily on the uninsured, who must pay list price.
read article 

Statement from American Society of Hematology President Charles S. Abrams, MD, on ASH Recommendations for the National Cancer Moonshot Initiative

(ASH) Apr 26, 2016 - Today the American Society of Hematology (ASH) met with the White House to share scientific recommendations for the National Cancer Moonshot, an initiative spearheaded by Vice President Joe Biden that aims to make a decade’s worth of progress in cancer research in the next five years.
read press release 

ImmunoGen Hires Former Shire, Genzyme Exec As New CEO

(Boston Business Journal/BioFlash blog) Apr 26, 2016 - One of the area’s largest developers of cancer drugs, ImmunoGen, has named a former Shire and Genzyme executive as its new CEO.
read article 

How an Open-Science Advocate Aims To Shake Up Pharma

(STAT) Apr 26, 2016 - Dr. Jay Bradner, a decorated cancer researcher from the Dana-Farber Cancer Institute, turned heads last year when he accepted a top job at Novartis, one of the world’s largest drug makers.
read article 

U.S. Biotechnologist Robert Langer Named European Inventor Award 2016 Finalist

(PRWEB) Apr 26, 2016 - The European Patent Office (EPO) today announced that M.I.T. Professor Robert Langer has been named as one of three finalists for the European Inventor Award 2016 in the category “Non-European countries.”
read press release 

Biocept Collaborates with MedStar Georgetown University Hospital for Liquid Biopsy Study

(Morningstar) Apr 27, 2016 - Biocept, Inc. announces the initiation of a collaborative study with MedStar Georgetown University Hospital to evaluate resistance biomarkers in patients diagnosed with non-small cell lung cancer (NSCLC) who are currently being treated with EGFR inhibitors or chemotherapy.
read article 

Biotech Startup Provides Functional Studies on Thousands of Breast Cancer Gene Variants

(BioScience Technology) Apr 27, 2016 - Toronto-based biotech startup, Ranomics, has launched a database that for the first time, provides functional studies on the impact of 2,000 variants of BRCA1, which is a gene associated with hereditary breast and ovarian cancers.
read article 

Dana-Farber and Fitbit Partner To Test If Weight Loss Can Prevent Breast Cancer Recurrence

(Dana-Farber) Apr 27, 2016 - Dana-Farber is teaming up with Fitbit to test if weight loss can help prevent breast cancer recurrence among overweight women with early stage disease. This first of its kind study has potential to create a new standard of treatment for millions of breast cancer patients around the world.
read press release 

Montco Pharma Firm Partners With Mayo Clinic, National Cancer Institute On Study

(Philadelphia Business Journal) Apr 27, 2016 - Inovio Pharmaceuticals, Inc. is teaming up with the National Cancer Institute and the Mayo Clinic to test its experimental immunotherapy as a potential treatment for hepatitis C.
read article 

Vietnam Vets Push VA to Link Bladder Cancer to Agent Orange

(The Virginian-Pilot/ProPublica) Apr 27, 2016 - Alan Eller has spent more than a decade trying to convince the Department of Veterans Affairs that his bladder cancer was the result of exposure to Agent Orange almost 50 years ago in Vietnam.
read article 

Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors

(Agenus) Apr 27, 2016 - Agenus Inc., an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in the company’s Phase 1 clinical trial of AGEN1884, an anti-CTLA-4 checkpoint (CPM) antibody.
read corporate press release 

BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer

(Morningstar) Apr 27, 2016 - BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase II clinical trial for its drug candidate BPM 31510 in combination with gemcitabine for the potential treatment of pancreatic cancer.
read article 

Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer

(Yahoo! Finance) Apr 27, 2016 - Celldex Therapeutics, Inc. today announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC) of the lung, who have progressed on prior platinum-based chemotherapy.
read article 

Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer

(Morningstar) April 27, 2016 - Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, today announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial ovarian cancer.
read article 

Targeted Photoimmunotherapy Approach for Cancer Moves Forward

(NCI/Cancer Currents Blog) Apr 25, 2016 - Two new studies from NCI researchers add to growing evidence of the promise of a novel type of cancer immunotherapy that uses infrared light to activate rapid and selective killing of cancer cells.
read article 

How Many Nanoparticle-Based Drugs Reach Tumours? Less Than One Per Cent, U Of T Engineering Study Shows

(University of Toronto Engineering) Apr 26, 2016 - Targeting cancer cells for destruction while leaving healthy cells alone — that has been the promise of the emerging field of cancer nanomedicine. But a new meta-analysis from U of T’s Institute of Biomaterials & Biomedical Engineering (IBBME) indicates that progress so far has been limited and new strategies are needed if the promise is to become reality.
read article 

MicroRNA Pathway Could Lead To New Avenues For Leukemia Treatment

(UC Academic Health Center) Apr 26, 2016 - Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
read press release